INTEGRA LIFESCIENCES HOLDINGS CORP
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
IART$14.53+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
(Dollars in thousands, except per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Total revenue, net | $391,918 | $382,653 |
| Costs and expenses: | ||
| Cost of goods sold | 174,936 | 188,221 |
| Research and development | 23,501 | 24,728 |
| Selling, general and administrative | 178,235 | 181,497 |
| Intangible asset amortization | 3,776 | 3,704 |
| Total costs and expenses | 380,448 | 398,150 |
| Operating income (loss) | 11,470 | (15,497) |
| Interest income | 4,106 | 4,420 |
| Interest expense | (22,465) | (18,815) |
| Other income (expense), net | 4,480 | (144) |
| Loss before income taxes | (2,409) | (30,036) |
| Provision for income taxes | 2,208 | (4,743) |
| Net loss | $(4,617) | $(25,293) |
| Net loss per share | ||
| Basic and diluted | $(0.06) | $(0.33) |
| Weighted average common shares outstanding (See Note 13): | ||
| Basic and diluted | 76,951 | 76,463 |
| Comprehensive loss (See Note 14) | (5,480) | (21,828) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.